Health topic

Hepatitis B (HBV)

A commitment to innovative
diagnostics and treatment

A silent, yet life-threatening infection

Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). An estimated 257 million people worldwide are chronically infected with HBV,1 and more than 2 million die each year due to complications such as cirrhosis and liver cancer.2

HBV Worldwide Statistic

While there is no cure for hepatitis B, it can be prevented. Currently available vaccines are 95% effective in inhibiting infection and the subsequent development of chronic disease.3


What makes hepatitis B so dangerous?

Hepatitis B is a contagious liver disease that ranges in severity from a mild illness lasting a few weeks to a serious, lifelong illness.

Acute & Chronic HBV

Most people display no symptoms upon initial infection with HBV, and they often aren’t diagnosed until the onset of advanced liver disease. In the meantime, they can unknowingly spread the virus through sexual contact and exchange of bodily fluids. In fact, hepatitis B is 50–100 times more infectious than HIV.4

Efforts to treat the infection can be hindered by limited access to proper diagnostics and medication.


Detection and treatment of HBV


There are many different blood tests available to diagnose hepatitis B.

  • Serological testing is performed to determine the presence of antibodies in response to a hepatitis B infection
  • Molecular tests determine the amount of HBV in the blood at baseline and as a response to treatment and can be powerful tools for making proper treatment decisions
3 Types of Viral Hepatitis

Improving testing efficiency provides clinicians with actionable data to enhance the patient care they provide. There is no medication available to treat acute hepatitis B. People with chronic hepatitis B should be monitored regularly for signs of liver disease and evaluated for possible treatment.

Roche continues to search for new and innovative ways to prevent, diagnose and treat HBV, while working to further enable access to those in need. Our portfolio of highly sensitive and accurate assays plays a critical role in screening blood, plasma and organ donors and supports clinicians in the effective management of chronic HBV infections.

Related systems
cobas® 4800 System

Highly efficient, flexible workflows and a consolidated assay menu deliver confidence with every result. Automated PCR setup and analysis help make the most of your resources and reduce error.

Learn More
cobas® 6800 System

Unparalleled performance, absolute automation, and unmatched flexibility. Meet the needs of molecular testing today and experience the freedom to explore the possibilities for tomorrow.

Learn More
cobas® 8800 System

Unparalleled performance with minimal operator interaction revolutionizes the future of highthroughput applications.

Learn More


  1. World Health Organization (WHO), Hepatitis B, Published July 18, 2018. Accessed March 21, 2019
  2. National Center for Biotechnology Information (NCBI), Burden of liver diseases in the world. Published January 2019. Asccessed on March 21, 2019
  3. World Health Organization (WHO), Hepatitis B, Published July 18, 2018. Accessed March 21, 2019
  4. Hepatitis B Foundation, HIV?HBV Co-Infection. Published Decmber 6, 2017. Accessed March 21, 2019
Found 0 results in